Axovant Sciences Ltd. (NASDAQ:AXON)’s share price was up 7.8% during trading on Monday . The company traded as high as $5.39 and last traded at $5.38. Approximately 1,356,381 shares were traded during trading, an increase of 32% from the average daily volume of 1,030,785 shares. The stock had previously closed at $4.99.

A number of equities analysts have commented on AXON shares. Jefferies Group LLC set a $40.00 target price on Axovant Sciences and gave the company a “buy” rating in a report on Friday, August 25th. BidaskClub cut Axovant Sciences from a “hold” rating to a “sell” rating in a report on Tuesday, October 17th. Evercore ISI began coverage on Axovant Sciences in a report on Friday, September 8th. They issued an “outperform” rating and a $30.00 price target for the company. Chardan Capital reissued a “sell” rating and set a $3.00 target price on shares of Axovant Sciences in a research note on Saturday, September 23rd. Finally, Zacks Investment Research raised Axovant Sciences from a “hold” rating to a “strong-buy” rating and set a $8.00 target price for the company in a research note on Monday, October 9th. Four equities research analysts have rated the stock with a sell rating, five have assigned a hold rating and six have issued a buy rating to the company. The stock presently has a consensus rating of “Hold” and an average price target of $14.13.

The company has a debt-to-equity ratio of 0.34, a current ratio of 5.94 and a quick ratio of 5.94.

A number of large investors have recently added to or reduced their stakes in AXON. FMR LLC boosted its holdings in Axovant Sciences by 968.5% in the second quarter. FMR LLC now owns 7,235,632 shares of the biotechnology company’s stock valued at $167,794,000 after purchasing an additional 6,558,462 shares during the period. Janus Henderson Group PLC purchased a new stake in Axovant Sciences during the 2nd quarter worth about $47,854,000. OxFORD Asset Management LLP lifted its holdings in Axovant Sciences by 842.1% during the 3rd quarter. OxFORD Asset Management LLP now owns 869,834 shares of the biotechnology company’s stock worth $5,838,000 after buying an additional 777,505 shares during the last quarter. Capital Research Global Investors lifted its holdings in Axovant Sciences by 21.8% during the 2nd quarter. Capital Research Global Investors now owns 3,453,800 shares of the biotechnology company’s stock worth $80,094,000 after buying an additional 619,226 shares during the last quarter. Finally, Eagle Asset Management Inc. purchased a new stake in Axovant Sciences during the 3rd quarter worth about $4,471,000. Hedge funds and other institutional investors own 99.69% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This news story was reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this news story on another site, it was illegally copied and reposted in violation of U.S. and international trademark and copyright legislation. The correct version of this news story can be accessed at https://www.thecerbatgem.com/2017/11/22/axovant-sciences-ltd-axon-trading-up-7-8.html.

Axovant Sciences Company Profile

Axovant Sciences Ltd. is a clinical-stage biopharmaceutical company. The Company is focused on acquiring, developing and commercializing therapeutics for the treatment of dementia, including Alzheimer’s disease and Lewy body dementia. The Company intends to develop a pipeline of product candidates to address the cognitive, functional and behavioral aspects of dementia and related neurological disorders.

Receive News & Stock Ratings for Axovant Sciences Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axovant Sciences Ltd. and related stocks with our FREE daily email newsletter.